NL
DE
Aiosyn, a Radboudumc spin-off and pioneering innovator in AI-powered pathology software for cancer and kidney disease, has announced that its algorithm for mitotic figure counting has achieved CE marking under the In Vitro Diagnostic Regulation (IVDR) for use in diagnostics. This milestone establishes Aiosyn Mitosis Breast as the first IVDR-certified application for mitosis counting in breast cancer diagnostics and accelerates the company’s growth in clinical pathology.
Read the full news release at Aiosyn Mitosis Breast becomes the first AI-powered mitosis detection solution to achieve CE mark certification under IVDR - Aiosyn
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Boosting the startup ecosystem in Nijmegen!
22 June 2023TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.
read more
Aiosyn selected as finalist for OostNL's Startversneller vote now!
18 October 2022The 6 finalists of the election “Starter with impact Eastern Netherlands 2022” have been announced and Radboudumc’s Aiosyn is one of them.
read more.aspx?width=800&height=534&ext=.jpg&type=BlockColumn1Zoom1)
Aiosyn and Radboudumc are the first in the Netherlands to implement AI in the clinical pathology workflow Digital pathology slides will be screened with a quality control algorithm
4 April 2022 Aiosyn, a company that develops AI-powered computational pathology analysis for clinical diagnostics, and the department of pathology of Radboudumc, will collaborate to implement an algorithm for quality control of digitized histopathology tissue slides. read more
